Home›The Library›Vancomycin
Vancomycin
Vancomycin is one of the oldest and most important antibiotics still in daily hospital use — a glycopeptide approved in 1958, before modern efficacy-trial requirements existed, and still the frontline drug for MRSA despite a real, ongoing story of emerging resistance.
On this page
In brief
Should you care? Relevant if you're researching MRSA treatment or hospital antibiotic protocols — this is a genuinely foundational drug in modern infectious disease.The short version
- Approved in 1958, years before the 1962 law requiring controlled efficacy trials — its approval rests on preclinical and small clinical data by today's standards, not a modern trial.
- Early production was impure ("Mississippi mud"), causing infusion reactions later blamed on the drug itself rather than manufacturing quality.
- Real resistance has emerged — VRE by the late 1980s, and rare VRSA cases from direct gene transfer.
A cell-wall-blocking glycopeptide
Vancomycin is a glycopeptide — not a simple peptide, but a peptide-backbone molecule — that binds the D-alanyl-D-alanine terminus of peptidoglycan precursors, physically blocking the cross-linking reactions that build the bacterial cell wall. It was isolated from a soil bacterium (originally named Streptomyces orientalis, now Amycolatopsis orientalis) collected in Borneo by an Eli Lilly chemist in the early 1950s.
"Mississippi mud" and a pre-modern approval
The FDA approved vancomycin in 1958, driven by urgency over emerging penicillin-resistant staph infections — years before the 1962 Kefauver-Harris amendments required the randomized controlled efficacy trials modern drugs need. Early fermentation-derived batches were poorly purified, brown and muddy in appearance (nicknamed "Mississippi mud" by the scientists who made it), and associated with infusion reactions and kidney injury that later purification of the compound substantially reduced — a real reminder that some of the drug's early reputation for toxicity was at least partly a manufacturing-quality problem, not solely the molecule itself.
Modern monitoring, and the resistance story
Vancomycin dosing has become more precise over time: a 2020 consensus guideline (Rybak et al., Am J Health Syst Pharm 2020) shifted practice from simple trough-level monitoring to AUC/MIC-guided dosing specifically to reduce nephrotoxicity while maintaining efficacy. Resistance has been a real, evolving concern since the late 1980s, when vancomycin-resistant enterococci (VRE) first emerged; by the early 1990s more than 10% of US hospital enterococcal isolates were vancomycin-resistant. In rarer, more serious cases, the resistance gene transferred directly from VRE to MRSA, producing vancomycin-resistant S. aureus (VRSA) in a small number of documented US patients in the early 2000s.
Current status
Still a frontline, widely used antibiotic — the drug most hospitals reach for first against MRSA — available generically, with IV formulations for systemic infections and a separate oral formulation used specifically for C. difficile colitis (oral vancomycin isn't absorbed systemically, so it stays in the gut where that infection lives). No wellness or grey-market presence; this is a hospital/clinic-administered prescription antibiotic.
References
- Levine DP, "Vancomycin: A History," Clin Infect Dis 2006;42(Suppl 1):S5-S12.
- Rybak MJ, Le J, Lodise TP, et al., "Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline," Am J Health Syst Pharm 2020;77(11):835-864.
- FDA approval history for vancomycin, 1958 (predates modern controlled-trial approval standards).